Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005837 | 1.00 | LMNA (0.67) | LMNAKMT2AMEN1NPC1TDP1 | |
| SCHEMBL8920256 | 0.86 | LMNA (0.54) | LMNATP53GAAMAPTSLC6A3 | |
| SCHEMBL10280718 | 0.85 | LMNA (0.63) | LMNAKMT2AMEN1NPC1TDP1 | |
| SCHEMBL13522407 | 0.85 | LMNA (0.66) | LMNAKMT2AMEN1NPC1TDP1 | |
| SCHEMBL880483 | 0.84 | LMNA (0.62) | LMNAKMT2AMEN1NPC1TDP1 | |
| SCHEMBL880444 | 0.84 | TP53 (0.59) | LMNAKMT2AMEN1TP53MAPT | |
| SCHEMBL880376 | 0.83 | ALDH1A1 (0.58) | LMNAKMT2AMEN1NPC1TDP1 | |
| SCHEMBL7156373 | 0.83 | ALDH1A1 (0.58) | LMNAKMT2AMEN1NPC1TDP1 | |
| SCHEMBL12698414 | 0.83 | ALDH1A1 (0.58) | LMNAKMT2AMEN1NPC1TDP1 | |
| SCHEMBL10280290 | 0.82 | LMNA (0.70) | LMNAKMT2AMEN1NPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072490-B | High-efficiency synthesis method of tipifarnib quinolinone intermediate | 中国海洋大学 | 2022-08-16 | — | — | CN | claimed |
| CN-113072490-A | High-efficiency synthesis method of tipifarnib quinolinone intermediate | 中国海洋大学 | 2021-07-06 | — | — | CN | claimed |
| CN-113072490-B | High-efficiency synthesis method of tipifarnib quinolinone intermediate | 中国海洋大学 | 2022-08-16 | — | — | CN | disclosed |
| CN-113072490-A | High-efficiency synthesis method of tipifarnib quinolinone intermediate | 中国海洋大学 | 2021-07-06 | — | — | CN | disclosed |
| US-20130289022-A1 | TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2358370-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | Link Medicine Corporation (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110060005-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-20100331363-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2002024683-A1 | FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
| EP-1162201-A2 | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-12-12 | — | — | EP | disclosed |
| US-6169096-B1 | FOR INHIBITING TUMOR GROWTH IN A MAMMAL | JANSSEN PHARMACAEUTIC N.V. (BE) | 2001-01-02 | — | — | US | disclosed |
| EP-0988038-A1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-29 | — | — | EP | disclosed |
| US-6037350-A | USEFUL AS ANTICANCER AGENTS FOR TUMORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-03-14 | — | — | US | disclosed |
| CN-1203598-A | Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1998-12-30 | — | — | CN | disclosed |
| WO-1998055124-A1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-10 | — | — | WO | disclosed |
| EP-0865440-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997021701-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060005-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | NLN, FNTA, ACAT1 | LMNA 1392/4885KMT2A 1658/4885MEN1 1419/4885 |
| US-20100331363-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | NLN, ACAT1, FH | LMNA 1206/4885KMT2A 2316/4885MEN1 1484/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | LMNA 2407/4885KMT2A 1852/4885MEN1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.